-- Partnership Expands Invitae’s Global Presence
into Mexico, Costa Rica, & Panama --
SAN FRANCISCO
and MEXICO CITY― July 30, 2014 ― Invitae Corporation, a genetic information
company, and Nanopharmacia, the leading oncology molecular test provider in
Mexico, today announced an exclusive partnership to make Invitae’s genetic
tests for the management of hereditary cancers broadly available throughout
Mexico. In addition, the partnership
includes access on a non-exclusive basis in Costa Rica and Panama.
Nanopharmacia will offer Invitae’s hereditary
cancer panels and BRCA1/BRCA2 offering to a
wide network of onco-geneticists and medical and surgical oncologists.
Invitae’s oncology offering includes the
following:
- Single gene BRCA1 and BRCA2, including full
gene sequencing and deletion/duplication analysis
- High-risk hereditary breast cancer panel (6
genes)
- Women’s hereditary cancer panel (18 genes
associated with hereditary breast, ovarian and endometrial cancer)
- Hereditary cancer syndromes panel (29 genes)
- Hereditary Pancreatic Cancer Panel (17 genes)
- Additional hereditary cancer panels are
available, including testing for Lynch Syndrome and colon cancers
“This partnership with Nanopharmacia provides
clinicians and their patients with reliable, fast and affordable genetic
testing while also advancing our mission to make genetic testing more
accessible to patients in need around the globe,” said Lisa Alderson of
Invitae. “Nanopharmacia has been a
leader in Mexico in embracing molecular medicine as a cornerstone to guide
patient care, and we are proud to work with such a dedicated and well-respected
organization to help improve the health of patients.”
The partnership includes access for advanced next
generation genetic testing in Mexico through a network of approximately 800
oncology professionals in Mexico, as well as in Costa Rica and
Panama.
“Genetic information is critical to improving the
care of patients with hereditary cancers, and we believe that the adoption of
Invitae’s tests will significantly help patients in Mexico and other
territories we service,” said Horacio Astudillo, chairman of the board at
Nanopharmacia. “Nanopharmacia is committed to bringing high-quality innovation
to help patients with cancer.”
About Nanopharmacia
Nanopharmacia Diagnostica is an operational unit
that performs molecular tests of high and low complexity for the personalized
diagnosis of cancer and other diseases, in order to support patients in México
and Latin America. Nanopharmacia is composed of a group of experts in the
biomolecular field, specializing in cancer genomics and molecular oncology.
Nanopharmacia works with the highest quality standards, certified by
ISO-9001:2008, Applus and RENIECYT. Focusing its business in life and health,
through its division Life Science Solutions, Nanopharmacia provides solutions
for the pharmaceutic industry, hospitals, biotechnological laboratories and
related industries.
About Invitae
Corporation
Invitae is a genetic information company whose mission is to bring
genetic information into routine medical practice to improve the quality of healthcare
for billions of people. Specializing in
genetic diagnostics for hereditary disorders, Invitae is aggregating the
world’s genetic tests into a single service with better quality, faster
turnaround time, and a lower price than most single-gene diagnostic tests
today. Invitae has raised $87 million
from investors, including Thomas McNerney Partners, Casdin Capital, Genesys
Capital, Genomic Health, Inc. (NASDAQ: GHDX), and Redmile Group. For further information, please visit www.invitae.com.
Contacts:
Invitae:
Katherine Stueland
pr@invitae.com
844-233-4492
Nanopharmacia Diagnóstica SA de CV:
01 800 910 6266
+55 52 64 28 15